0001209191-20-063474.txt : 20201215
0001209191-20-063474.hdr.sgml : 20201215
20201215162434
ACCESSION NUMBER: 0001209191-20-063474
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201211
FILED AS OF DATE: 20201215
DATE AS OF CHANGE: 20201215
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Polymeropoulos Mihael Hristos
CENTRAL INDEX KEY: 0001355537
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-34186
FILM NUMBER: 201389838
MAIL ADDRESS:
STREET 1: 9605 MEDICAL CENTER DRIVE SUITE 300
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Vanda Pharmaceuticals Inc.
CENTRAL INDEX KEY: 0001347178
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 030491827
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2200 PENNSYLVANIA AVE NW
STREET 2: SUITE 300E
CITY: WASHINGTON
STATE: DC
ZIP: 20037
BUSINESS PHONE: 202-734-3400
MAIL ADDRESS:
STREET 1: 2200 PENNSYLVANIA AVE NW
STREET 2: SUITE 300E
CITY: WASHINGTON
STATE: DC
ZIP: 20037
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-12-11
0
0001347178
Vanda Pharmaceuticals Inc.
VNDA
0001355537
Polymeropoulos Mihael Hristos
2200 PENNSYLVANIA AVENUE
SUITE 300E
WASHINGTON
DC
20037
1
1
0
0
President and CEO
Common Stock
2020-12-11
4
M
0
41817
8.75
A
1320816
D
Common Stock
2020-12-11
4
S
0
35053
12.8765
D
1285763
D
Common Stock
2020-12-14
4
M
0
61520
8.75
A
1347283
D
Common Stock
2020-12-14
4
S
0
51049
13.1894
D
1296234
D
Common Stock
2020-12-15
4
M
0
46663
8.75
A
1342897
D
Common Stock
2020-12-15
4
S
0
39150
12.9973
D
1303747
D
Employee Stock Option (Right to Buy)
8.75
2020-12-11
4
M
0
41817
0.00
D
2020-12-15
Common Stock
41817
108183
D
Employee Stock Option (Right to Buy)
8.75
2020-12-14
4
M
0
61520
0.00
D
2020-12-15
Common Stock
61520
46663
D
Employee Stock Option (Right to Buy)
8.75
2020-12-15
4
M
0
46663
0.00
D
2020-12-15
Common Stock
46663
0
D
Represents shares of the Issuer's common stock sold to satisfy the exercise price and certain tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the exercise of certain stock options, which were scheduled to expire December 15, 2020 as reflected in this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.80 to $13.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.15 to $13.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.85 to $13.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4.
The option vested in 48 equal monthly installments from the date of grant.
/s/ Mihael Polymeropoulos
2020-12-15